Dandrit Biotech Usa, Inc. (DDRT) SEC Filing 8-K Material Event for the period ending Monday, November 13, 2017

Dandrit Biotech Usa, Inc.

CIK: 1527728 Ticker: DDRT

View differences made from one to another to evaluate Dandrit Biotech Usa, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Dandrit Biotech Usa, Inc..


Assess how Dandrit Biotech Usa, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Dandrit Biotech Usa, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Material Contracts, Statements, Certifications & more

Dandrit Biotech Usa, Inc. provided additional information to their SEC Filing as exhibits

Ticker: DDRT
CIK: 1527728
Form Type: 8-K Corporate News
Accession Number: 0001213900-17-012297
Submitted to the SEC: Fri Nov 17 2017 5:18:42 PM EST
Accepted by the SEC: Fri Nov 17 2017
Period: Monday, November 13, 2017
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. New Agreement
  3. New Financial Obligation

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: